These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38332555)

  • 1. CD11c
    El Mahdaoui S; Hansen MM; von Essen MR; Hvalkof VH; Holm Hansen R; Mahler MR; Jennum P; Sellebjerg F; Romme Christensen J
    Ann Clin Transl Neurol; 2024 Apr; 11(4):926-937. PubMed ID: 38332555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis.
    Cuculiza Henriksen A; Ammitzbøll C; Petersen ER; McWilliam O; Sellebjerg F; von Essen MR; Romme Christensen J
    Mult Scler Relat Disord; 2021 Jul; 52():102987. PubMed ID: 33984651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
    Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
    Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients.
    Boldrini VO; Marques AM; Quintiliano RPS; Moraes AS; Stella CRAV; Longhini ALF; Santos I; Andrade M; Ferrari B; Damasceno A; Carneiro RPD; Brandão CO; Farias AS; Santos LMB
    Front Immunol; 2022; 13():750660. PubMed ID: 35197967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
    Blumenfeld S; Staun-Ram E; Miller A
    J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained effects on immune cell subsets and autoreactivity in multiple sclerosis patients treated with oral cladribine.
    Holm Hansen R; von Essen MR; Reith Mahler M; Cobanovic S; Sellebjerg F
    Front Immunol; 2024; 15():1327672. PubMed ID: 38433828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The B1-cell subpopulation is diminished in patients with relapsing-remitting multiple sclerosis.
    Tørring C; Petersen CC; Bjerg L; Kofod-Olsen E; Petersen T; Höllsberg P
    J Neuroimmunol; 2013 Sep; 262(1-2):92-9. PubMed ID: 23856341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
    J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
    Gingele S; Jacobus TL; Konen FF; Hümmert MW; Sühs KW; Schwenkenbecher P; Ahlbrecht J; Möhn N; Müschen LH; Bönig L; Alvermann S; Schmidt RE; Stangel M; Jacobs R; Skripuletz T
    Cells; 2018 Dec; 8(1):. PubMed ID: 30597851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
    Rodriguez-Mogeda C; van Lierop ZYGJ; van der Pol SMA; Coenen L; Hogenboom L; Kamermans A; Rodriguez E; van Horssen J; van Kempen ZLE; Uitdehaag BMJ; Teunissen CE; Witte ME; Killestein J; de Vries HE
    J Neuroinflammation; 2023 Sep; 20(1):215. PubMed ID: 37752582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell Depletion.
    Shirani A; Stuve O; Cross AH
    Neurol Clin; 2024 Feb; 42(1):137-153. PubMed ID: 37980111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific myeloid signatures in peripheral blood differentiate active and rare clinical phenotypes of multiple sclerosis.
    Vakrakou AG; Paschalidis N; Pavlos E; Giannouli C; Karathanasis D; Tsipota X; Velonakis G; Stadelmann-Nessler C; Evangelopoulos ME; Stefanis L; Kilidireas C
    Front Immunol; 2023; 14():1071623. PubMed ID: 36761741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocrelizumab associates with reduced cerebrospinal fluid B and CD20
    van Puijfelik F; Blok KM; Klein Kranenbarg RAM; Rip J; de Beukelaar J; Wierenga-Wolf AF; Wokke B; van Luijn MM; Smolders J
    Brain Commun; 2024; 6(1):fcae021. PubMed ID: 38385000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases.
    Defendenti C; Atzeni F; Malandrin S; Ardizzone S; Almasio PL; Saibeni S; Bezzio C; Bollani S; Salerno R; Declich P; Sarno Z; Bruno S; Talotta R; Sarzi-Puttini P
    Int Immunopharmacol; 2018 Jan; 54():329-335. PubMed ID: 29197269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
    Frisch ES; Pretzsch R; Weber MS
    Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis.
    Nissimov N; Hajiyeva Z; Torke S; Grondey K; Brück W; Häusser-Kinzel S; Weber MS
    Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25690-25699. PubMed ID: 32999069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-beta treated-multiple sclerosis patients exhibit a decreased ratio between immature/transitional B cell subset and plasmablasts.
    Monteiro A; Cruto C; Rosado P; Rosado L; Fonseca AM; Paiva A
    J Neuroimmunol; 2019 Jan; 326():49-54. PubMed ID: 30476705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
    Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
    PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of CD11c+CD5+ chronic B-cell leukemias and the identification of novel peripheral blood B-cell subsets with chronic lymphoid leukemia immunophenotypes.
    Wormsley SB; Baird SM; Gadol N; Rai KR; Sobol RE
    Blood; 1990 Jul; 76(1):123-30. PubMed ID: 1694698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral helper T cells in the pathogenesis of multiple sclerosis.
    Holm Hansen R; Højsgaard Chow H; Talbot J; Buhelt S; Nickelsen Hellem MN; Nielsen JE; Sellebjerg FT; von Essen MR
    Mult Scler; 2022 Aug; 28(9):1340-1350. PubMed ID: 35112578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.